All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body ...

The biotechnology company priced its offering of 10.2 million shares at $16 apiece, at the high-end of its targeted range of $14 to $16 each. The IPO valued the company at $482.5 million. Newer weight ...